Scott J. Rodig, Ph.D., M.D.
This page shows the publications co-authored by Scott Rodig and Ralph Mazitschek.
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012 Mar 15; 119(11):2579-89.
The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM). J Clin Oncol. 2011 May 20; 29(15_suppl):e18569.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.